Objectives: The aim of this study was to evaluate the effect of levetiracetam on tardive dyskinesia (TD), which is known to be a major limitation of chronic antipsychotic drug therapy, particularly with conventional antipsychotics.
T ardive dyskinesia (TD) is known to be a major limitation of chronic antipsychotic drug therapy, particularly conventional antipsychotics, 1 having the atypical antipsychotics' fewer extrapyramidal adverse effects.
There is no known effective treatment for TD, and its pathophysiology is not clear.
Levetiracetam is a novel antiepileptic drug used in the treatment of partial crises as an add-on to other antiepileptic drugs. 2 Although the underlying mechanism of action of levetiracetam is unknown, it might counteract the neuronal hypersynchronization of the firing patterns of neurons in the substantia nigra pars reticulate and globus pallidus pars interna 3 that are considered critical structures for the development of dyskinesia. 4 Levetiracetam at a dose of 60 mg/kg decreased levodopa-induced dyskinesias (LIDs) and potentiated the antidyskinetic action of amantadine 5 in animal models of
Parkinson disease (PD) and in a small group of parkinsonian patients; 6 however, a recent open-label observational study showed that levetiracetam was a poorly tolerated drug and did not effectively control LIDs in 16 parkinsonian patients.
7
A positive response to levetiracetam in one patient suffering from TD has suggested a possible role of this drug in the treatment of TD. 8 The aim of this study was to evaluate the effect of levetiracetam on TD.
MATERIALS AND METHODS
Sixteen patients suffering from chronic psychosis with TD were enrolled consecutively. All patients were fully informed about the aims of the study and all gave their written informed consent. The study was performed using an open-label observational design. The neuroleptic treatment given to the patients was not changed at any time during the trial. Levetiracetam was given in gradually increasing doses, starting with 125 twice a day (in the morning and in the evening); this dose was raised by 125 mg twice a day every week until a dose of 500 mg twice a day was reached; it was then raised by 500 mg every 5 days up to 2000 mg/d, or until a satisfactory result was achieved. The patients were observed up to 3 months by means of monthly checkups performed by the same neurologist at the same hour of the day and using the Abnormal Involuntary Movement Scale (AIMS) each time: baseline (T0), 1 month (T1), and 3 months (T3).
The difference between times was evaluated by means of nonparametric 1-way repeated measures analysis of variance (Friedman test) followed by the Dunn multiple comparison test.
RESULTS
The clinical features of the patients with TD are listed in Table 1 . Dyskinesia affected the orofacial region and the tongue (n = 10 patients), the arms and the trunk (n = 3 patients), and the arms and the lower limbs (n = 3 patients). The drugs responsible for TD were haloperidol (n = 5), thioridazine (n = 2), pimozide (n = 1), risperidone (n = 1), and olanzapine (n = 1). These medications were not withdrawn and their dosage was not modified throughout the study. Additional medications were furosemide (n = 2) and ticlopidine (n = 3). Fifteen of the 16 patients concluded the study; one patient dropped out of the trial after the first 2 weeks owing to excessive drowsiness.
Levetiracetam decreased significantly the AIMS score compared with baseline (P G 0.0001, Friedman test), and persistently after 3 months of treatment (T1: P G 0.0001; T3: P G 0.0001, Dunn test).
In 5 patients treated with levetiracetam for more than 6 months, efficacy on TD and safety were permanent and constant for all time.
The following adverse effects were documented among the 15 patients ending the trial: slight drowsiness (n = 5), feeling of confusion (n = 3), and subjective vertigo (n = 1). These adverse effects were present at titration time and ceased spontaneously after 2 weeks of treatment. None of the adverse effects interfered with the psychotic symptoms.
DISCUSSION
Our study shows that levetiracetam at a mean dosage of 2200 mg effectively treats TD and is well tolerated. Abnormal Involuntary Movement Scale score decreased by 61% and 59%, respectively, after 1 and 3 months of treatment, without a worsening of psychiatric symptoms and with a very low rate of dropout (1 patient of 16). Slight drowsiness was the most common adverse effect.
Levetiracetam is a novel antiepileptic drug useful as add-on treatment in intractable partial epilepsy with an unclear mechanism of action. 2 The effectiveness in TD might be associated with its ability to reduce neuronal hypersynchronization as seen in an animal model of epilepsy. 9 This feature has provided the rationale for using levetiracetam in LIDs in PD because they are in part caused by abnormal synchronization within the basal ganglia. 3 However, in a previous study, we found that levetiracetam is ineffective in the treatment of LIDs in PD and is associated with a high dropout rate (50%) owing to sleepiness, probably because of the pharmacological interactions with L-dopa and dopamine agonists. 7 The reason for the difference in the effect of levetiracetam in TD and LID is unclear. The higher mean dosage of levetiracetam may explain the positive results in patients with TD (2290 mg daily in TD; range, 1000Y3000 mg vs 1375 mg daily in PD; range, 250Y2000 mg). 7 Moreover, the opposite result might be explicated by the different pathophysiology of these hyperkinetic disorders. Indeed, LID is presumably caused by a decrease in the firing rate and pattern of the globus pallidus pars interna and to an alteration of NMDAmediated synaptic plasticity in the striatum secondary to dopaminergic denervation, 10 whereas in TD, dopaminergic terminals are intact and dyskinesia might be triggered by increased sensitivity to dopamine. 1 In fact, chronic administration of neuroleptics evokes adaptive changes in dopamine receptors, causing an increase in the number of D2 receptors and supersensitivity of D1 receptors. 4 Along with the reduction in neuronal synchronization, levetiracetam might act by selectively blocking N-type calcium channels in the striatum, as described in rat hippocampal neurons. 11 Another hypothesis is that striatal NMDA transmission might be a target of levetiracetam because long-term neuroleptic treatment may increase the NMDA-mediated corticostriatal glutamate transmission, leading to striatal excitotoxicity. 12 In fact, TD symptoms seem to correlate positively with markers of excitatory neurotransmission and negatively with cerebrospinal fluid superoxide dismutase activity in schizophrenic patients, suggesting the presence of elevated levels of oxidative stress and glutamatergic neurotransmission in TD. 13 In rats, the levetiracetam infusion is associated with an increase in nitric oxide induced by NMDA. 14 In brain synapses, nitric oxide synthase activation is coupled to NMDA-mediated calcium entry at postsynaptic densities through regulatory protein complexes, and NMDA/nitric oxide inhibits the release of presynaptic glutamate. 15 Levetiracetam could modulate the sodiumdependent glutamate, as the result of its activity on astrocytes. 14 In conclusion, levetiracetam, given in gradually increasing doses from 125 mg twice a day to 1000 mg twice or three times a day, is an effective and safe drug in chronic psychotic patients with TD. Because the study was open and based on a limited number of patients, further controlled studies on larger series of patients are warranted to confirm our data.
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